IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 285,500 shares, a decline of 52.3% from the February 28th total of 598,100 shares. Based on an average daily trading volume, of 378,700 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the company’s shares are sold short.

IceCure Medical Trading Up 0.5 %

Shares of NASDAQ:ICCM traded up $0.01 during midday trading on Friday, hitting $1.11. 221,593 shares of the stock were exchanged, compared to its average volume of 521,961. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.27 and a current ratio of 2.67. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The business’s 50-day moving average price is $1.32 and its 200 day moving average price is $0.98. The stock has a market capitalization of $61.61 million, a price-to-earnings ratio of -3.83 and a beta of 0.37.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. Analysts predict that IceCure Medical will post -0.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a report on Friday.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC boosted its holdings in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,453 shares of the company’s stock after purchasing an additional 14,893 shares during the period. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.